Cystic fibrosis-related diabetes and lung disease: an update,European Respiratory Review

当前位置： X-MOL 学术 › Eur. Respir. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cystic fibrosis-related diabetes and lung disease: an update
European Respiratory Review ( IF 9.0 ) Pub Date : 2021-02-16 , DOI: 10.1183/16000617.0293-2020
Bernadette J Prentice _{1,

2} , Adam Jaffe _{2,

3} , Shihab Hameed _{2,

4,

5} , Charles F Verge _{2,

5} , Shafagh Waters _{2,

6} , John Widger _{2,

3}

Affiliation

The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.

中文翻译：